Vigabatrin

Vigabatrin is a prescription anti-seizure drug that works by raising GABA, the brain's main calming neurotransmitter, and keeping it elevated. It was designed in the 1970s with that exact target in mind. Today it's mostly used in two narrow medical settings: infantile spasms in babies (where it's first-line for tuberous sclerosis), and refractory focal seizures in adults who haven't responded to other anti-epileptics. Outside those uses, it sits in a regulatory grey zone people experiment with for cocaine and methamphetamine cravings, and very occasionally for severe anxiety, because cranking up GABA blunts the dopamine spike that drives stimulant compulsion.

The reason vigabatrin isn't taken casually is the side effect profile. Long-term use damages the peripheral retina in roughly 25-50% of adults, and that damage is permanent. This is not a nootropic or a daily compound. If you're considering it, the realistic use cases are short courses (weeks to a few months) under medical supervision with baseline and follow-up vision testing built in.

Deep-dive

Vigabatrin (also called γ-vinyl-GABA or VGB) is a structural analogue of GABA with an extra vinyl group. It doesn't bind GABA receptors directly. Instead, it acts as an irreversible suicide inhibitor of GABA transaminase (GABA-T), the enzyme that breaks GABA down inside neurons and glia. Once vigabatrin binds GABA-T, that enzyme molecule is dead until the cell makes a new one. This means the drug's biological half-life is far longer than its plasma half-life of around 5-8 hours, the effect lasts as long as it takes to resynthesise enough GABA-T to restore normal turnover, which is typically several days. Brain GABA concentrations climb several-fold and stay elevated.

Elevated GABA shifts the brain toward inhibition. In epilepsy, that suppresses the runaway excitatory firing that produces a seizure. In tuberous sclerosis complex, where mTOR pathway dysregulation appears to disrupt GABAergic transmission, vigabatrin is unusually effective, up to 95% of infants with TSC-related infantile spasms achieve complete cessation of spasms, compared to roughly 50-55% in non-TSC infantile spasms.

Cocaine and methamphetamine. This is where vigabatrin gets attention outside epilepsy clinics. Stimulant addiction is driven by dopamine surges in the nucleus accumbens. Animal work in the late 1990s showed that raising GABA blunts those dopamine spikes by inhibiting the dopaminergic neurons of the ventral tegmental area. The translational work followed: an open-label trial in 30 cocaine and methamphetamine users reported abstinence rates that were unusually high for this population. A randomised, double-blind, placebo-controlled trial of 103 cocaine-dependent adults found significantly more vigabatrin-treated subjects achieved abstinence in the last 3 weeks of the dosing period than placebo. A separate ocular safety pilot in cocaine and methamphetamine users dosed for 9 weeks found no measurable visual field changes. Larger follow-up trials, including a Phase II/III industry-sponsored study and a University of Pennsylvania trial, terminated early or returned weaker results, so the picture is mixed and the FDA never approved the indication. Practically, the addiction-treatment use case is short-course (8-12 weeks), where the visual field risk is low.

Why vision is the problem. Vigabatrin concentrates in retinal tissue at 5-18 times the brain concentration. The mechanism of toxicity isn't fully settled but appears multifactorial: excessive GABA in the retina drives excitotoxic ion shifts in retinal cells, ocular blood flow drops, reactive oxygen species rise, and there's strong evidence that taurine deficiency contributes, vigabatrin depletes taurine, and taurine is critical to retinal ganglion cell survival. Light exposure also worsens the damage in animal models. The result is a characteristic pattern of bilateral, concentric peripheral visual field loss with the central field largely spared, often asymptomatic until it's severe. Histology in affected adults shows peripheral retinal atrophy and ganglion cell loss. The damage is generally irreversible. Whether taurine supplementation prevents this in humans hasn't been adequately tested, animal data is suggestive but not yet a clinical recommendation.

Brain MRI changes. A separate concern, mostly seen in infants. Roughly 22-32% of babies treated for infantile spasms develop bilateral symmetric T2 hyperintensities and restricted diffusion in the globus pallidus, thalamus, brainstem and dentate nuclei. These usually resolve within about 3 months of stopping the drug and are typically asymptomatic, though a minority develop movement disorders or encephalopathy. Risk is dose-dependent and tied to younger age. This pattern hasn't been described in adults at the same frequency.

Women. Vigabatrin pharmacokinetics show no meaningful sex differences, and clinical trials for both epilepsy and infantile spasms have shown comparable anti-seizure efficacy between men and women, with no sex-specific dose adjustment recommended. Interestingly, some retrospective analyses suggest male sex is associated with higher risk of visual field defects, though the data is not strong enough to change monitoring practice. Vigabatrin doesn't significantly affect oral contraceptive metabolism, unlike older anti-epileptics. Pregnancy data is limited and the drug should be avoided unless seizure control demands it. A small amount enters breast milk at therapeutic doses, so caution applies during breastfeeding. Women with childbearing potential who use vigabatrin for epilepsy should be on a separate, non-hormonal-only contraceptive plan only because pregnancy outcomes are poorly characterised, not because of any drug interaction.

Limitations of the evidence. The cocaine and methamphetamine data is the most-cited reason people look at vigabatrin recreationally, but the evidence base is genuinely mixed, several of the most promising trials were industry-sponsored, terminated early, or showed effect sizes that didn't survive replication. The visual field risk data is solid for chronic high-dose use in adult epilepsy (25-50% prevalence after a year). Short-course addiction trials have not detected vision changes, but those trials are small and the longest only ran a few months. There is no body of safety data for healthy adults using vigabatrin for cognitive or anxiety purposes, and the drug has no upside in those settings that justifies the retinal risk.

Dosage:

Refractory focal/complex partial seizures (adults): Start at 500 mg twice daily. Titrate up by 500 mg/day per week as needed, up to a maximum of 1500 mg twice daily (3000 mg/day total). Doses above 3000 mg/day don't improve efficacy and increase side effects.

Infantile spasms (1 month-2 years): Initial dose 50 mg/kg/day divided in two, titrated to 100-150 mg/kg/day over a few days. Response is typically apparent within 2 weeks; if no response by 12 weeks, discontinue.

Off-label cocaine/methamphetamine addiction protocol (from published trials): 2-week titration from 1 g/day to 3 g/day, maintained for 6-9 weeks, then tapered. Total course typically 8-12 weeks. This is the dosing range where vision changes have not been detected in monitoring studies.

Timing: Twice daily with or without food. Food reduces Cmax by about 33% but doesn't meaningfully affect total absorption. Splitting the dose evenly across the day matters more than meal timing.

Renal dose adjustment: Vigabatrin is excreted unchanged by the kidneys. Reduce dose by 25-50% if creatinine clearance is below 60 mL/min. Older adults often need lower doses for this reason.

Discontinuation: Never stop abruptly in an epilepsy patient, taper over 2-4 weeks to avoid rebound seizures. For short addiction-protocol courses, taper over 1-2 weeks.

Forms: 500 mg tablets or 500 mg powder sachets for oral solution (mix only with cold or room-temperature water). Both are bioequivalent.

Here's what you can expect:

One-time use: basically nothing. Vigabatrin doesn't bind GABA receptors directly, it slowly disables the enzyme that breaks GABA down, so brain GABA accumulates over days, not minutes. A single dose produces no felt high, no anxiolytic punch, no real sedation beyond mild drowsiness at higher doses. Anyone expecting an acute effect like a benzo, phenibut, or alcohol will be disappointed. The mechanism only meaningfully kicks in with repeated daily dosing.

For epilepsy, the seizure-suppressing effect builds over the first 1-3 weeks of titration and stabilises once you're at maintenance dose. In responders, the reduction in seizure frequency is often substantial. In infantile spasms, response is typically very fast, within days to two weeks. If there's no response by 12 weeks, the drug isn't going to work and should be discontinued.

For stimulant cravings (off-label), users in the trial literature generally describe a noticeable drop in craving intensity and a flattening of the urge cycle within the first 1-2 weeks at therapeutic dose. The drug doesn't produce a felt 'high' or sedation at standard doses, more of a subtle quietening of the dopamine reward pull.

Side effects to expect across all uses: fatigue, drowsiness, mild dizziness, headache, and weight gain are common, especially in the first month. These usually settle but don't always. Some people report mild cognitive slowing or word-finding difficulty, particularly at higher doses.

What you won't notice (and this is the danger): the visual field constriction. It develops slowly over months, starts in the periphery, and is usually asymptomatic until it's already significant. The whole point of routine perimetry/OCT is to catch it before you would notice it yourself.

Side effects & risks:

Permanent peripheral visual field loss is the headline risk. Roughly 25-50% of adults on chronic vigabatrin develop measurable bilateral concentric visual field constriction. The damage is generally irreversible. Risk rises with cumulative dose and duration, with most cases appearing after 6+ months of treatment. Short courses (under 3 months) appear lower risk but not zero. This is not a drug to take without ophthalmologic monitoring.

Brain MRI changes in 22-32% of treated infants, usually asymptomatic and reversible after discontinuation, but a minority develop movement disorders. Less commonly described in adults at standard doses.

Sedation and fatigue in 25-40% of users, especially during titration. Often improves but doesn't always.

Weight gain of several kilograms is common with longer-term use.

Psychiatric effects: depression, agitation, irritability, occasionally psychosis. Risk is higher with rapid titration, high doses, and a prior psychiatric history. Suicidal ideation has been reported across all anti-epileptics including vigabatrin and is a class-level FDA warning.

Movement abnormalities: tremor, dystonia, hyperreflexia or hyporeflexia, paraesthesia. Usually mild.

Allergic and skin reactions: rare but include angioedema and very rarely Stevens-Johnson syndrome and toxic epidermal necrolysis. Stop immediately and seek medical care for any spreading rash.

Hepatic enzyme changes: vigabatrin can lower ALT and AST by inhibiting alanine transaminase, which means liver enzymes may look artificially reassuring. Don't rely on AST/ALT alone to monitor liver health while on vigabatrin.

Drug interactions: modestly lowers phenytoin levels (around 20%). Doesn't significantly affect oral contraceptives, lamotrigine, or carbamazepine. Avoid combining with other GABAergic drugs (high-dose benzodiazepines, baclofen, gabapentin, pregabalin, alcohol) at high doses, the additive sedation and cognitive impairment is real.

Pregnancy: limited data, congenital malformation risk is not well-characterised, avoid unless seizure control requires it.

Hard contraindications: pre-existing significant visual field defects, prior hypersensitivity, severe renal impairment without dose adjustment.

Taurine. Some clinicians supplement taurine (1-3 g/day) during vigabatrin courses based on the animal evidence that taurine deficiency contributes to retinal toxicity. Whether this prevents vision loss in humans hasn't been proven in a controlled trial, but the downside of taurine supplementation is essentially zero, so it's a reasonable hedge.

🩸

Monitoring & blood markers

Visual field testing (perimetry) and OCT of the retinal nerve fibre layer are the non-negotiables. Baseline before starting, then every 3 months while on the drug, and once more 3-6 months after stopping. OCT can detect retinal nerve fibre layer thinning before symptomatic field loss appears, and is more reliable than perimetry in patients who can't perform the visual field test well. This monitoring catches damage early enough to discontinue before it becomes severe, but cannot reverse damage that has already occurred.

Serum creatinine and eGFR, baseline and every 6 months. Vigabatrin is renally cleared and dose adjustment is needed below an eGFR of 60. Don't trust the dose if you don't know your kidney function.

Plasma taurine, optional but reasonable if running a longer course, since taurine depletion is implicated in retinal toxicity. Most labs can run this.

Note on liver enzymes: vigabatrin artificially lowers ALT and AST. If you want to monitor liver health, use GGT or bilirubin alongside, or expect ALT/AST to read low.

TSH and free T4 baseline if running longer-term, mainly because fatigue and weight gain on vigabatrin can mimic hypothyroidism and you want to be able to distinguish the two.

For someone using vigabatrin in a short addiction-treatment context (8-12 weeks), the minimum monitoring is baseline visual field test and OCT, repeat at end of course, and a creatinine check. Anyone running it longer needs the full 3-monthly ophthalmology workup.

Vigabatrin is a prescription drug under restricted distribution programs in most jurisdictions (the REMS program in the US). Use without medical supervision and ophthalmologic monitoring carries real risk of permanent vision loss.